Aditya Bardia, MBBS, MPH, discusses the development of targeted therapies for patients with triple-negative breast cancer. He says these approaches can be divided into 3 different categories.
Aditya Bardia, MBBS, MPH, a breast medical oncologist at Massachusetts General Hospital and Harvard Medical School, discusses the development of targeted therapies for patients with triple-negative breast cancer (TNBC). He says these approaches can be divided into 3 different categories.
The first category would be targeting oncogenes. An example of this would be the use of PARP inhibitors. Second, ongoing trials are also looking at intercellular signaling pathways, says Bardia.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More